SecSonar.com

ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

ImmunityBio, Inc. (IBRX) is a Biotechnology company based in US with a market capitalization of $7.9B. Revenue grew 668.3% year-over-year and free cash flow was negative at -$308.8M. This page tracks IBRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 671 employees · IPO Jul 28, 2015

Valuation

Valuation & price

$7.97 · as of May 17, 2026 · -31.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$11.55$6.77$1.98Jul 25Dec 25Jun 26Jul 7, 25$2.72Jul 9, 25$2.79Jul 11, 25$2.81Jul 15, 25$2.74Jul 17, 25$2.83Jul 21, 25$2.68Jul 23, 25$2.99Jul 25, 25$2.86Jul 29, 25$2.54Jul 31, 25$2.46Aug 4, 25$2.41Aug 6, 25$2.38Aug 8, 25$2.44Aug 12, 25$2.47Aug 14, 25$2.71Aug 18, 25$2.43Aug 20, 25$2.26Aug 22, 25$2.31Aug 27, 25$2.34Aug 29, 25$2.34Sep 3, 25$2.37Sep 5, 25$2.40Sep 9, 25$2.57Sep 11, 25$2.59Sep 15, 25$2.74Sep 17, 25$2.76Sep 19, 25$2.73Sep 23, 25$2.59Sep 25, 25$2.46Sep 29, 25$2.57Oct 1, 25$2.48Oct 3, 25$2.54Oct 7, 25$2.50Oct 9, 25$2.44Oct 13, 25$2.48Oct 16, 25$2.53Oct 20, 25$2.45Oct 22, 25$2.36Oct 24, 25$2.47Oct 28, 25$2.58Oct 30, 25$2.36Nov 3, 25$2.26Nov 5, 25$2.15Nov 7, 25$2.13Nov 11, 25$2.14Nov 13, 25$2.00Nov 17, 25$2.03Nov 19, 25$2.14Nov 21, 25$2.08Nov 25, 25$2.08Nov 28, 25$2.36Dec 2, 25$2.09Dec 5, 25$2.29Dec 9, 25$2.22Dec 11, 25$2.19Dec 15, 25$2.22Dec 17, 25$2.11Dec 19, 25$2.08Dec 23, 25$2.10Dec 26, 25$2.14Dec 30, 25$1.98Jan 2, 26$2.02Jan 6, 26$2.14Jan 8, 26$2.24Jan 12, 26$2.59Jan 14, 26$3.02Jan 16, 26$5.52Jan 21, 26$6.92Jan 23, 26$6.45Jan 28, 26$6.15Jan 30, 26$6.25Feb 3, 26$6.33Feb 5, 26$5.64Feb 9, 26$6.93Feb 11, 26$6.54Feb 13, 26$5.95Feb 18, 26$8.54Feb 20, 26$8.70Feb 24, 26$11.55Feb 26, 26$9.55Mar 2, 26$10.44Mar 4, 26$9.00Mar 6, 26$8.67Mar 10, 26$8.01Mar 12, 26$7.82Mar 16, 26$8.21Mar 19, 26$8.82Mar 23, 26$9.40Mar 25, 26$8.07Mar 27, 26$7.38Mar 31, 26$7.67Apr 2, 26$7.30Apr 7, 26$6.86Apr 9, 26$7.48Apr 13, 26$7.30Apr 15, 26$7.78Apr 17, 26$7.70Apr 21, 26$8.10Apr 23, 26$8.19Apr 27, 26$7.29Apr 29, 26$6.96May 1, 26$7.11May 5, 26$7.58May 8, 26$8.51May 12, 26$8.12May 14, 26$8.15May 18, 26$8.00May 20, 26$8.05May 22, 26$7.22May 27, 26$7.89May 29, 26$7.52Jun 2, 26$7.23Jun 4, 26$7.29Jun 8, 26$7.17Jun 10, 26$6.98Jun 12, 26$7.10Jun 16, 26$6.72Jun 18, 26$7.36Jun 23, 26$7.32Jun 29, 26$8.49
$1.9852-week range$11.55
Loading valuation history…

Fundamentals

Key fundamentals

$7.9B

Market cap

668.3%

Revenue growth (YoY)

99.3%

Gross margin

-$308.8M

Free cash flow (USD)

$635.3M

Net debt

31.9%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$44.0KFY 2017$45.0KFY 2018$47.0KFY 2019$43.0KFY 2020$605.0KFY 2021$934.0KFY 2022$240.0KFY 2023$622.0KFY 2024$14.7MFY 2025$113.3M
$44K$113.3M

Free cash flow by year

2016 → 2025

FY 2016$-45.2MFY 2017$-83.6MFY 2018$-76.5MFY 2019$-156.4MFY 2020$-173.4MFY 2021$-308.0MFY 2022$-415.7MFY 2023$-397.3MFY 2024$-398.1MFY 2025$-308.8M
-$45.2M-$308.8M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202599.3%
100.0%99.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $871K · 10b5-1 PlanSelecky Christobel · Director · $871.2KJul 1, 2026Filing
  • Insider sellInsider Sell $197K · 10b5-1 PlanSimon Barry J. · Director · $196.9KJun 26, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • 8-K eventExclusive Supply AgreementMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseApr 9, 2026Filing
  • 8-K eventFDA Response SubmittedApr 6, 2026Filing
  • 8-K eventAmendment to Purchase AgreementMar 31, 2026Filing

Questions

Frequently asked questions

What is ImmunityBio, Inc.'s market cap?

ImmunityBio, Inc. (IBRX) has a market capitalization of $7.9B.

What is IBRX's P/E ratio?

A meaningful P/E ratio is not available for IBRX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying IBRX stock?

SEC Form 4 filings show no open-market insider buys at ImmunityBio, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

HALO

Halozyme Therapeutics, Inc.

$8B

TECH

Bio-Techne Corporation

$8.1B

CORT

Corcept Therapeutics Incorporated

$7.5B

PRAX

Praxis Precision Medicines, Inc.

$7.2B

ALKS

Alkermes plc

$7.1B

KYMR

Kymera Therapeutics, Inc.

$6.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.